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Abstract
Chemotherapy with oxytetracycline in 
livestock is reportedly faced with 
increasing therapeutic failure and 
resistant bacteria strains circulating in 
humans, animals and the environment. 
This study determined the actual 
concentrations in some dosage forms of 
oxytetracycline available in Southwest 
Nigeria labelled for veterinary use by 
spectrophotometric method of analysis.
Eight 5% (50mg/ml) and four 20% 
(200mg/ml) preparations of injectable 
oxytetracycline were purchased from 
veterinary pharmacies in Ibadan. 
The mean concentration of oxytetracycline 
obtained from formulations ranged 
between 0.484mg/ml and 0.757 mg/ml. 
Al l  the commercial  formulations 
contained less than the labelled 
concentration when 1mg/ml of these 
samples was compared with 1mg/ml of the 
analytical grade of oxytetracycline. 
Therapy failures and development of 
bacterial resistance to oxytetracycline 
could therefore result from proliferation of 
fake  or  sub-standard drugs  and 
indiscriminate use or abuse.
There is need for strict regulation and 
quality control of importation, marketing 
and use of veterinary drugs in Nigeria. 
Also, there is need for pharmaco-vigilance 
a n d  p h a r m a c o - e p i d e m i o l o g i c a l  
investigation of chemotherapeutic agents, 
which is recommended to ensure their 
efficacy for animal health and food safety.
Introduction
Oxytetracycline is  obtained from 
Streptomyces rimosus, a soil actinomycete 
and is one of the first two members of the 
tetracycline group of antibiotics ever 
d i s c o v e r e d  ( K i m  e t  a l . ,  1 9 9 4 ) .  
Oxytetracycline hydrochloride (Syn: 5-
Hydroxytetracycline hydrochloride) is 
c h e m i c a l l y  r e c o g n i z e d  a s  [ 4 S -
(4alpha,4aalpha,5alpha,5aalpha,6beta,12
a a l p h a ) ] - 4 - ( D i m e t h y l a m i n o )  
1 , 4 , 4 a , 5 , 5 a , 6 , 1 1 , 1 2 a - o c t a h y d r o -
3,5,6,10,12,12a-hexahydroxy-6-methyl-
1,11-dioxo-2 naphthacenecarboxamide 
monohydrochloride (Fig 1). Tetracyclines 
act by inhibition of bacterial protein 
synthesis through prevention of the 
association of the bacterial ribosome with 
aminoacyl tRNA (Chopra et al., 1992; 
Schnappinger and Hillen, 1996). 
Tetracyclines are widely administered for 
prophylactic and therapeutic purposes, as 
well as at sub-therapeutic doses for growth 
promotion in livestock (Gustafson and 
Kiser, 1985; Karimuribo et al., 2005). Up 
till the 1950s, about 98% of commensals 
and pathogenic bacteria were reported 
sensitive to tetracycline (Levy, 1992). 
Resistance to tetracycline has since been 
on the increase and recent studies showed 
that about 85 to 91% of food-borne 
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pathogens were resistant to tetracycline 
(Ojo et al., 2009; Olatoye, 2010). 
Resistance to tetracycline have occurred 
due to their indiscriminate use and abuse 
in medical, veterinary and agricultural 
practices (Dina and Arowolo, 1991; Chopra 
and Roberts, 2001; Dipeolu, 2002).
In Nigeria, like in most developing 
countries, antibiotics are widely available 
over-the-counter and mostly used without 
prescriptions (Dina and Arowolo, 1991; 
Ezenduka et al., 2011). Withdrawal 
periods are not usually observed and 
residues have been reported in tissues of 
food animals and their products (Kabir et 
al., 2004; Olatoye and Ehinmowo, 2010). 
Several brands of tetracycline imported 
and sold in veterinary shops, livestock 
markets and by drug peddlers are routinely 
used by farmers without veterinary 
diagnosis or prescriptions (Dina and 
Arowolo, 1991; Fagbamila et al., 2010). 
Most of these drug formulations have been 
reported ineffective against tetracycline 
susceptible organisms (Ojo et al., 2009). 
WHO (2006) estimated that about 30% of 
medicines sold in Africa are counterfeit of 
which antimicrobial agents being the most 
popular target. Substandard products with 
lower-than-stated doses promote 
resistance, and those containing no 
antimicrobial drug at all promote 
microbial dissemination (Okeke et al., 
2007). The proliferation of fake or sub-
standard drugs could contribute to 
widespread resistance to numerous 
antibiotics with tetracycline resistance 
being one of the most common (Shakoor, 
et al., 1997). There is a large market for 
drugs in Nigeria with about 130 existing 
pharmaceutical manufacturers. Only 60 of 
these are actively manufacturing, while up 
to 70% of drugs are imported into the 
country (Okoli, 2000). The suspected 
s h a r p  p r a c t i c e s  b y  s o m e  d r u g  
manufacturers and importers in the 
production and packaging of drugs, and 
obvious therapy failures on the field 
necessitated this study. The study was 
designed to evaluate the concentrations of 
oxytetracycline in some formulations 
(brands) available in Nigeria for veterinary 
application using the spectrophotometric 
analytical method.
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Fig 1: Molecular structure of 
oxytetracycline hydrochloride
.
Molecular Formula C H N O HCl 2 2 2 4 2 9
Molecular Weight 496.90
MATERIALS and METHODS
Chemicals and reagents 
Analytical grade of oxytetracycline 
hydrochloride was purchased from Sigma-
Aldrich St. Louis, MO, USA. Random 
samples of commercially available 
injectable oxytetracycline brands for 
veterinary use [5% (50mg/ml) (n = 8) and 
20% (200mg/ml) (n = 4)] were purchased 
from veterinary pharmacies in Ibadan, 
Nigeria and these were used at least six 
months before their expiry dates. The drug 
samples included in the study were all 
i m p o r t e d  b r a n d s  w i t h  N a t i o n a l  
Administration of Food and Drug 
Administration (NAFDAC) registration 
identifications   and designated as A, B, C, 
D, E, F, G and H for 5% formulations, while 
the 20% formulations were designated as I, 
J, K, and L. HPLC-grade of methanol was 
also purchased from Sigma-Aldrich (USA).
Preparation of Standard curve
Laboratory grade analytical standard 
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oxytetracycline were accurately weighed 
and dissolved in methanol to produce 
different concentrations of 1, 0.75, 0.50, 
0.25 and 0.1mg/ml. The absorbances of 
these concentrations were measured in 
t r i p l i c a t e  a t  5 4 0 n m  o n  a  
spectrophotometer (SM22PC Surgienfield 
Instrument, England) after obtaining zero 
a b s o r b a n c e  w i t h  m e t h a n o l .  T h e  
calibration curve used in this study (Fig. 2) 
was prepared by obtaining linear 
relationship between these known 
concentrations of the standard and their 
absorbance. 
Sample preparation and test 
protocol
Dosage forms (commercial preparations) 
of injectable oxytetracycline (1mg/ml 
each) were dissolved in methanol and the 
absorbances of these solutions on the 
spectrophotometer at 540nm were 
recorded. The concentrations of these 
solutions were determined using the linear 
equation obtained from the known 
concentrations and corresponding 
absorbance of the standards curve of 
oxytetracycline. The procedure was 
repeated four times for each brand, and the 
mean values and standard error of mean 
were calculated.
The method was validated using relative 
standard deviation (RSD) obtained from 
the standard oxytetracycline and the 
2correlation coefficient (R ) of the standard 
curve.
Statistical analysis
The results obtained were expressed as 
mean values ± standard deviation (SD). 
Data were analysed using one way analysis 
of variance (ANOVA) on GraphPad Prism 
4.0 version. The statistical significant 
difference between the mean values were 
determined at p<0.05. 
RESULTS 
The 5% formulations of oxytetracycline 
were presented as brands A, B, C, D, E, F, G 
or H, while the 20% formulations were 
presented as brands I, J, K or L. The mean 
concentrations of oxytetracycline obtained 
for the 5% (50mg/ml) formulations ranged 
b e t w e e n  3 6 . 2 m g / m l  ( 3 . 6 % )  a n d  
37.9mg/ml (3.8%) which is between 24.3 - 
2 7 . 5 %  l e s s  t h a n  t h e  s t a n d a r d  
oxytetracycline as shown in Table I, while 
the mean concentration of the 20% 
(200mg/ml) oxytetracycline samples 
ranged between 96.8mg/ml (9.7%) and 
101.2mg/ml (10.1%) (Table II). 
All the formulations contained less than 
the labelled oxytetracycline concentration 
indicated values. Significantly lower 
concentrations were obtained in drugs A, 
E, G, I, J and K. Most of the 20% 
oxytetracycline brand samples contained 
less than 50% of the concentrations 
indicated by their manufacturers, while 
the 5% oxytetracycline brands had about 
30% 
less than the expected concentrations (Table 1).
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relative to 5% labelled 
A 1.446±0.006 0.7471 74.71 37.4 (3.7%) 
B 1.440±0.004 0.7386 73.86 36.9 (3.7%) 
C 1.446±0.005 0.7476 74.76 37.4 (3.7%) 
D 1.446±0.003 0.7471 74.71 37.4 (3.7%) 
E 1.429±0.003 0.7247 72.47 36.2 (3.6%) 
F 1.451±0.003 0.7538 75.38 37.7 (3.8%) 
G 1.436±0.012 0.7332 73.32 36.7 (3.7%) 
H 1.454±0.003 0.7574 75.74 37.9 (3.8%) 
     
 











Concentration (mg/ml) of 
oxytetracycline relative to 
20% labelled 
I 1.258±0.005 0.4944 49.44 98.9 (9.9%) 
J 1.260±0.013 0.4962 49.62 99.2 (9.9%) 
K 1.251±0.006 0.4841 48.41 96.8 (9.7%) 
L 1.267±0.003 0.5061 50.61 101.2 (10.1%) 
DISCUSSION
T h e  v a l u e s  o f  o x y t e t r a c y c l i n e  
concentration obtained for all drug 
formulations evaluated in this study were 
found lower than what is indicated on their 
labels. The method used was found to be 
2linear (R > 0.94), the linear relationship in 
the calibration curve of the standard 
oxytetracycline, while accuracy and 
precision of the method was shown by RSD 
< 4 . 2 1 %  o b t a i n e d  f r o m  s t a n d a r d  
oxytetracycline. The result of this study 
therefore implies that most of the 
commercially available oxytetracycline 
brands for veterinary use in the studied 
area were sub-standard as they contained 
lower concentrations of the active 
ingredients below the manufacturer's 
claims. The sub-standard antibiotic 
formulations imply that there is an 
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ongoing widespread administration of 
sub-therapeutic doses of antibiotics to sick 
animals which has its attendant problems 
including but not limited to; therapy 
failure, development and spread of 
resistant strains of micro-organisms in 
human and animal populations (Okonko 
et al., 2008; Nkang et al., 2010). 
Several years of medical exploitation of 
antimicrobial chemotherapy, particularly 
in treatment of human infections, has 
imposed an enormous selection pressure 
on formerly sensitive bacteria to acquire 
genetic elements that code for resistance to 
antibiotics (Prescott et al., 2000; Nkang et 
al., 2010). Administration of sub-
therapeutic doses to sick animals will no 
doubt serve to increase incidences of 
diseases and elevate the virulence of the 
microorganisms that evolve after such 
exposure. Severe economic losses are 
usually the fall out of uncurtailed disease 
outbreaks due to unmitigated increased 
morbidity and mortality (Okeke et al., 
2007). Aside this, development of 
resistance by microorganisms to 
antibiotics lead to heavy loss of revenue by 
genuine drug manufacturers due to 
evolvement of resistance in what was 
formerly sensitive organisms (Okeke and 
Sosa, 2011). 
The reduction in the concentrations of the 
antibiotic formulations could also have 
been as a result of degradation of the active 
compounds in the storage process as 
appropriately manufactured drugs could 
also become substandard due to improper 
storage. The storage methods adopted by 
manufacturers and retailers of these drugs 
should be evaluated for possible 
contributions to degradation of drugs on 
the shelf. Okeke et al., (2007) stated that 
antibiotics are unstable at ambient tropical 
conditions, but shelf lives and packaging 
are not adapted to preserve drug potency 
or mark their degradation in countries 
where these drugs are most needed. Proper 
storage in the tropics requires expensive 
electrical equipment, a constant storage 
temperature, pharmaceutical handling 
expertise, and an efficient supply chain, 
which do not exist in many parts of Africa. 
Storage methods should be standardized 
to ensure drug quality is maintained and 
prevent  future  re-occurrence  o f  
diminishing quality. The environmental 
temperature of the tropical region should 
also be considered for drugs exported from 
temperate regions.
The low quality of these drugs could have 
encouraged the practices of indiscriminate 
use, abuse and overuse of antibiotics in 
food-producing animals to achieve growth 
promotion and therapeutic results from 
these drugs. This has become of enormous 
concern in recent times due to increase in 
resistant bacterial strains in humans 
(National Research Council, 1999; Okesola 
and Oni, 2009; Okonko et al., 2009). 
Policies regulating antibiotic use vary from 
one country to another. Many countries 
have highlighted the need for better 
control of licensing of antibiotics and 
codes for prudent use by veterinary 
practitioners and farmers. In most 
developed countries, antibiotics intended 
for animal use are assessed for their 
potential to compromise human health. In 
such countries there is control-of-use 
legislation that restricts antibiotics 
registered for therapeutic or prophylactic 
use to registered veterinary surgeons, but 
allows over-the-counter sales to farmers or 
stock-feed companies of products 
registered for use as growth promoters 
(Barton, 2000). In Nigeria there is a 
palpable preponderance of sub-quality 
pharmaceutical  products  and al l  
veterinary antibiotics are sold over the 
counter. Osibo (1998) posited a strong and 
urgent need for stricter regulation and 
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quality control of importation, marketing 
and use of veterinary drugs in Nigeria. 
Regulatory organs of the government such 
as National Administration of Food and 
Drug Administration (NAFDAC) must 
strive to enforce the extant laws in order to 
evaluate and monitor the quality of 
veterinary drugs manufactured or 
imported into Nigeria. The establishment 
of functional veterinary directorate in 
NAFDAC as approved by the Federal 
Government of Nigeria could be a positive 
step towards addressing these problems. 
This may appear a daunting task 
considering the low level of requisite 
technology in the country, but it pales into 
insignificance when compared to likely 
adverse outcome on both human and 
animal populations.    
In conclusion, since a higher percentage of 
drugs used in this Nigeria are either 
imported wholly or merely packaged in the 
c o u n t r y ,  r o u t i n e  p h a r m c o -
epidemiological studies are necessary. All 
the drugs sampled in this study are 
imported drugs.  It does appear that 
uncontrolled importation of drugs in 
Nigeria has encouraged sharp practices 
which place commercial motive or gain 
over ethical considerations. There is 
therefore an urgent need for enforcement 
of appropriate drug regulations and 
pharmaco-epidemiological surveillance of 
veterinary drugs in Nigeria to ensure their 
consistent efficacy for effective animal 
health and human safety.
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